Match!

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study

Published on May 1, 2019in The Lancet Psychiatry
· DOI :10.1016/S2215-0366(19)30048-3
M. Di Forti10
Estimated H-index: 10
(Mental Health Foundation),
Marta Di Forti36
Estimated H-index: 36
(Mental Health Foundation)
+ 84 AuthorsElsje van der Ven7
Estimated H-index: 7
Sources
Abstract
Summary Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. Methods We included patients aged 18–64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ9-tetrahydrocannabinol (THC) in the different types of cannabis available across the sites, we divided the types of cannabis used by participants into two categories: low potency (THC Findings Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2–4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5–6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0–16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2–40·0) in London and 50·3% (27·4–66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109). Interpretation Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health. Funding source Medical Research Council, the European Community's Seventh Framework Program grant, Sao Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.
  • References (37)
  • Citations (126)
📖 Papers frequently viewed together
138 Citations
1,071 Citations
207 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References37
Newest
#1Wayne Hall (UQ: University of Queensland)H-Index: 93
#2Michael T. Lynskey ('KCL': King's College London)H-Index: 89
: The sale of cannabis for adult recreational use has been made legal in nine US states since 2012, and nationally in Uruguay in 2013 and Canada in 2018. We review US research on the effects of legalization on cannabis use among adults and adolescents and on cannabis-related harms; the impact of legalizing adult recreational use on cannabis price, availability, potency and use; and regulatory policies that may increase or limit adverse effects of legalization. The legalization of recreational ca...
10 CitationsSource
#1Lynn D. SilverH-Index: 1
#2Amanda Z. NaprawaH-Index: 1
Last. Alisa A. PadonH-Index: 1
view all 3 authors...
Importance As marijuana continues to be legalized in many states, little is known about best regulatory practice, exposing the population to significant potential harm. Objective To assess the extent to which potential best practices, including those from tobacco control, were incorporated into state and local marijuana policies in California. Design and Setting California legalized medical marijuana in 1996 and adult recreational use in 2016, effective in January 2018. A cross-sectional study w...
2 CitationsSource
#1Lindsey A. Hines (UoB: University of Bristol)H-Index: 8
#2Tom P. Freeman (UCL: University College London)H-Index: 25
Last. Jon Heron (UoB: University of Bristol)H-Index: 55
view all 9 authors...
Importance Cannabis use is consistently linked to poorer mental health outcomes, and there is evidence that use of higher-potency cannabis increases these risks. To date, no studies have described the association between cannabis potency and concurrent mental health in a general population sample or addressed confounding using longitudinal data. Objective To explore the association between cannabis potency and substance use and mental health outcomes, accounting for preceding mental health and f...
2 CitationsSource
#1Marco Colizzi (University of Verona)H-Index: 16
#2Mirella Ruggeri (University of Verona)H-Index: 46
Last. Sagnik Bhattacharyya ('KCL': King's College London)H-Index: 37
view all 3 authors...
Research evidence suggests a dose-response relationship for the association between cannabis use and risk of psychosis. Such relationship seems to reflect not only an increased risk of psychosis as a function of frequent cannabis use, but also of high-potency cannabis use in terms of concentration of delta-9-tetrahydrocannabinol (∆9-THC), its main psychoactive component. This finding would be in line with the evidence that ∆9-THC administration induces transient psychosis-like symptoms in otherw...
4 CitationsSource
#1Chandni Hindocha (UCL: University College London)H-Index: 14
#2Diego Quattrone (Mental Health Foundation)H-Index: 11
Last. Marta Di Forti (Mental Health Foundation)H-Index: 36
view all 10 authors...
Epidemiological and biological evidence support the association between heavy cannabis use and psychosis. However, it is unclear which cannabis users are susceptible to its psychotogenic effect. Therefore, understanding genetic factors contributing to this relationship might prove an important strategy to identify the mechanisms underlying cannabis-associated psychotic experiences. We aimed to determine how variation in AKT1, COMT and FAAH genotypes, and their interaction with three different gr...
1 CitationsSource
#1H. Valerie Curran (UCL: University College London)H-Index: 4
#1H. Valerie Curran (UCL: University College London)H-Index: 34
Last. Tom P. Freeman (UCL: University College London)H-Index: 25
view all 6 authors...
BACKGROUND: Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual's risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like symptoms. METHOD: In a naturalistic study, 410 young cannabis users were a...
13 CitationsSource
#1Antti Mustonen (OUH: Oulu University Hospital)H-Index: 4
#2Solja Niemelä (University of Oulu)H-Index: 22
Last. Jouko Miettunen (OUH: Oulu University Hospital)H-Index: 45
view all 7 authors...
BACKGROUND: The association between cannabis use and the risk of psychosis has been studied extensively but the temporal order still remains controversial. Aims To examine the association between cannabis use in adolescence and the risk of psychosis after adjustment for prodromal symptoms and other potential confounders. METHOD: The sample (n = 6534) was composed of the prospective general population-based Northern Finland Birth Cohort of 1986. Information on prodromal symptoms of psychosis and ...
15 CitationsSource
#1David Potter (GW Pharmaceuticals)H-Index: 5
#2Kathy Hammond (GW Pharmaceuticals)H-Index: 1
Last. M. Di Forti ('KCL': King's College London)H-Index: 10
view all 5 authors...
In 2005 and 2008, studies reported that cannabis in England had become dominated by the sinsemilla (unseeded female) form. The average potency (Δ9-tetrahydrocannabinol [THC] content) of this material had doubled over the previous decade. Cannabis resin then circulating contained approximately equal ratios of THC and cannabidiol (CBD), whereas sinsemilla was almost devoid of CBD. Despite raised health concerns regarding sinsemilla use and the development of psychotic disorders, no update on stree...
24 CitationsSource
#1Tom P. Freeman ('KCL': King's College London)H-Index: 25
#2Pol van der PH-Index: 12
Last. Michael T. Lynskey ('KCL': King's College London)H-Index: 89
view all 11 authors...
Background The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor. Methods Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ -9-tetrahydrocannabinol (THC) from the most popular variety of domestic herbal cannabis sold in each retail outlet (2000–2015). Mixed effect...
37 CitationsSource
#1Hannah E. JongsmaH-Index: 4
#2Charlotte Gayer-Anderson ('KCL': King's College London)H-Index: 16
Last. James B. Kirkbride (UCL: University College London)H-Index: 31
view all 27 authors...
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme. The Brazilian study was funded by grant 2012/0417-0 from the Sao Paulo Research Foundation. Dr Kirkbride is funded by the Wellcome Trust and grant 101272/Z/13/Z from the Royal Society. Ms Jongsma and Dr Jones are funded by the National Institute of Health Resea...
83 CitationsSource
Cited By126
Newest
Abstract Objective To evaluate if cannabis dose recorded as standard joint unit (SJU) consumed before admission and other related factors have an influence on psychiatric inpatient's symptom severity and clinical outcomes. Methods Cross-sectional study in an acute psychiatric inpatient unit including 106 individuals. Quantity of cannabis was measured as SJU and symptoms severity through the Brief Psychiatric Rating Scale (BPRS). Secondary outcomes (e.g. length of stay) were also assessed. Bivari...
Source
Background Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects.
1 CitationsSource
Abstract Despite the high prevalence in patients with schizophrenia, the association of cannabis and nicotine use with negative symptoms remains unclear. We performed a meta-analysis of observational studies addressing the association of cannabis and nicotine use with negative symptoms. Twenty cannabis studies (n = 2611) and 45 nicotine studies (n = 8942) were analyzed. There was no significant effect for current cannabis use alone or in combination with other substances. However, recently absti...
Source
#1Tessa Manning (OU: University of Oklahoma)
#2Christine Bartow (OU: University of Oklahoma)
Last. Zephan Chen (OU: University of Oklahoma)
view all 5 authors...
Abstract Several troubling trends in cannabis use have converged in recent years. The average concentration of psychoactive tetrahydrocannabinol in cannabis has steadily increased while the concentration of psychoprotective cannabidiol has fallen. 1 This trend coincides with a wave of legalization as well as novel methods for consuming marijuana, quite often in the form of “vaping” concentrated oils with concentrations of THC up to 80%. 6 Recent literature also reveals significant psychiatric mo...
Source
#1Faith Borgan (Imperial College London)H-Index: 6
#2Michelle Kokkinou (Imperial College London)H-Index: 3
Last. Oliver D. Howes (Imperial College London)H-Index: 57
view all 3 authors...
Abstract Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid receptor 1 may be a potential therapeutic target. In view of this, we first provide an overview of the endocannabinoid system and systematically review the evidence for cannabinoid 1 receptor alterations in animal models of schizophrenia and clinical studies in schizophre...
Source
#1Sadhana Dharmapuri (UIC: University of Illinois at Chicago)
#2Kathleen K. Miller (UMN: University of Minnesota)H-Index: 1
Last. Jonathan D. Klein (UIC: University of Illinois at Chicago)H-Index: 35
view all 3 authors...
Cannabinoids, the psychoactive compounds in marijuana, are one of the most commonly used substances in the United States. In this review, we summarize the impact of marijuana on child and adolescent health and discuss the implications of marijuana use for pediatric practice. We review the changing epidemiology of cannabis use and provide an update on medical use, routes of administration, synthetic marijuana and other novel products, the effect of cannabis on the developing brain, other health a...
Source
#1Tom P. Freeman (UCL: University College London)H-Index: 25
#2Valentina Lorenzetti (ACU: Australian Catholic University)H-Index: 23
BACKGROUND AND AIMS: Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on how units should be ...
20 CitationsSource
#1Morten Hesse (AU: Aarhus University)H-Index: 21
#2Lotte Vallentin-Holbech (AU: Aarhus University)
Last. Kristine Rømer Thomsen (AU: Aarhus University)H-Index: 10
view all 3 authors...
Source
#1Luca ZamengoH-Index: 8
#2Giampietro FrisonH-Index: 22
Last. Tom P. Freeman (University of Bath)H-Index: 25
view all 5 authors...
Cannabis contains over a hundred of different cannabinoids, of which Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most well studied. The use of high-potency cannabis, containing high...
Source
#1Ariel Dunn (University of Newcastle)
#2Patricia T. Michie (University of Newcastle)H-Index: 57
Last. Lauren Harms (University of Newcastle)H-Index: 13
view all 4 authors...
Abstract Many factors and their interaction are linked to the aetiology of schizophrenia, leading to the development of animal models of multiple risk factors and adverse exposures. Differentiating between separate and combined effects for each factor could better elucidate schizophrenia pathology, and drive development of preventative strategies for high-load risk factors. An epidemiologically valid risk factor commonly associated with schizophrenia is adolescent cannabis use. The aim of this r...
Source